ABSTRACT

The aim of this retrospective clinical-epidemiological study is to investigate the causes of an increase in the number of cases with malignant pleural mesotheliom observed at the INER from January 2006 to December 2009. This study comprised 149 in-patients with histopatological diagnose or malignant pleural mesothelioma. Clinical radiographic records were examined considering the following information: genre, age, smoking habits, family history of neoplastic disorders, asbestos exposure, clinical features, laboratory exams, and histological examination of pleural biopsy specimens. Results: An increase of malignant pleural mesothelioma was confirmed amongst INER in-patients. It was most commonly found in male patients. The average age of these patients was between 50-70 years-old. The importance of the immunohistochemical study was confirmed for establishing the diagnosis of the disease of pleural liquid and tumor biopsies. Asbestos was found to be the main cause of this disease. The INER and other Specialized Hospitals where cancer is treated constitute the ultimate link in the Aguilar-Madrid prognoses of an outbreak caused by the transfer to Mexico of manufacturing industries of asbestos-related products that have been banned in Europe, USA, and Canada. Taking into account that this condition is inevitably progressive, the only prevention is to legislate and eliminate asbestos-related industries in Mexico.

KEYWORDS

Epidemiology, asbestos, tumor markers, immunohistopatology.

REFERENCES

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408.

2. Corson JM. Pathology of mesothelioma. Thorac Surg Clin 2004;14:447-460.

3. Godleski JJ. Role of asbestos in etiology of malignant pleural mesothelioma. Thorac Surg Clin 2004;14:479-487.

4. Roggli VL, Gibbs AR, Attanoos R, et al. Pathology of asbestosis– An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med 2010;134:462-480.

5. Roach HD, Davies GJ, Attanoos R, Crane M, Adams H, Phillips S. Asbestos: when the dust settles an imaging review of asbestos-related disease. Radiographics 2002;22 Spec No:S167-S184.

6. Sebastien P, Janson X, Gaudichet A, Hirsch A, Bignon J. Asbestos retention in human respiratory tissues: comparative measurements in lung parenchyma and in parietal pleura. IARC Sci Publ 1980;(30):237-246.

7. Zellos L, Christiani DC. Epidemiology, biologic behavior and natural history of mesothelioma. Thorac Surg Clin 2004;14:469-77,viii.

8. Orpella X, Ramírez L, Schlaghecke J. Enfermedades relacionadas con el asbesto. FMC 2007;14:610-616.

9. Selikoff IJ, Churg J, Hammond EC. Asbestos exposure and neoplasia. JAMA 1964;188:22-26.

10. Selikoff IJ, Churg J, Hammond EC. Relation between exposure to asbestos and mesothelioma. N Engl J Med 1965;272:560-565.

11. Selikoff IJ, Hammond EC, Seidman H. Mortality experience of insulation workers in the United States and Canada, 1943-1976. Ann N Y Acad Sci 1979;330:91-116.

12. Kukreja J, Jaklitsch MT, Wiener DC, Sugarbaker DJ, Burgers S, Baas P. Malignant pleural mesothelioma: overview of the North American and European experience. Thorac Surg Clin 2004;14:435-445.

13. Harding AH, Darnton AJ. Asbestosis and mesothelioma among British asbestos workers (1971-2005). Am J Ind Med 2010;53:1070-1080.

14. WHO. Summary consensus report of WHO workshop on mechanisms of fibre carcinogenesis and assessment of chysotile asbestos substitutes. World Health Organization, Lyon, France. Geneva; 2005, 8-12 November.

15. Gavira SL, Marín LM, Urtiga DM. El asbesto y la salud en la Ciudad de México: un caso de transferencia del riesgo y del consumo. Salud Problema 1990;19:31-45.

16. García-López MP, Barrera RR. Mesotelioma maligno: descripción clínica y radiológica de 45 casos con y sin exposición a asbesto. Salud Pública Mex 2000;42:511-519.

17. Méndez-Vargas MM, López-Rojas P, Campos-Pujal GA, Marín-Cotoñieto IA, Salinas-Tovar S, Fernández-Muñoz MJ. Mesotelioma pleural en pacientes con exposición paraocupacional y ocupacional a asbesto ambiental. Rev Med Inst Mex Seg Soc 2010;48:361-366.

18. Barrera RR, Chavarría GJ, Morales FJ. Mesotelioma maligno: Experiencia clínico-patológica de 247 casos. Rev Chil Enf Respir 2010;26:134-140.

19. Aguilar-Madrid G, Juárez-Pérez CA, Markowitz S, Hernández-Avila M, Sánchez-Roman FR, Vázquez-Grameix JH. Globalization and the transfer of hazardous industry: asbestos in Mexico, 1979-2000. Int J Occup Environ Health 2003;9:272-279.

20. Carlos-Rivera F, Aguilar-Madrid G, Gómez-Montenegro PA, et al. Estimation of health-care costs for work-related injuries in the Mexican Institute of Social Security. Am J Ind Med 2009;52:195-201.

21. IARC, Lyon. IARC monographs on the evaluation of the carcinogenic risk of chemicals to man: asbestos. Monogr Eval Carcinog Risk Chem Man: Asbestos 1977;14:1-106.

22. Bates SE. Clinical applications of serum tumor markers. Ann Intern Med 1991;115:623-638.

23. Bueno R, Gordon GJ. Genetics of malignant pleural mesothelioma: molecular markers and biologic targets. Thorac Surg Clin 2004;14:461-468.

24. Robinson BW, Creaney J, Lake R, et al. Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 2003;362:1612-1616.

25. Lumb PD, Suvarna SK. Metastasis in pleural mesothelioma. Immunohistochemical markers for disseminated disease. Histopathology 2004;44:345-352.

26. WHO. Resolution concerning asbestos. In: Ninety-fifth International Labour Conference, Geneva, 31 May-16 June 2006. Report of the Committee on Safety and Health. Geneva, International Labour Conference. Annex 20/69.